Irina Soljanik1. 1. Neuro-Urology, Spinal Cord Injury Center, Heidelberg University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany. irasol@hotmail.com
Abstract
BACKGROUND: Botulinum toxin A (BoNTA) is increasingly used for therapy of neurogenic detrusor overactivity (NDO) refractory to antimuscarinics or where patients are experiencing antimuscarinic-related side effects. OBJECTIVE: The objective was to compare and critically discuss the reported efficacy and safety of BoNTA in adults with neurogenic bladder dysfunction. DATA SOURCES: Studies published between January 1985 and July 2012 were identified in the MEDLINE (PubMed) and SCOPUS databases. STUDY SELECTION, STUDY APPRAISAL AND SYNTHESIS METHODS: A search for studies with onabotulinumtoxinA--the only formulation of BoNTA approved by the US FDA in adults with NDO--was performed. Exclusion criteria were urethral sphincter injection, no separate analysis between onabotulinumtoxinA and other formulations of BoNTA, mean follow-up ≤ 4 weeks and studies with ten or fewer patients. Clinical and urodynamic parameters for efficacy, adverse events (AEs) and tolerability were reviewed to offer recommendations for practice and future research. RESULTS: A total of 28 included studies revealed superior effects of onabotulinumtoxinA compared with placebo in achieving continence, reducing incontinence episodes, improving urodynamic parameters and health-related quality of life. The most frequently reported AEs were de novo intermittent catheterization, urinary retention and asymptomatic urinary infection. LIMITATIONS: Limitations of this review are the inclusion of studies with the level-3 evidence (22/28 studies), the heterogenicity of outcome parameters and time points chosen for follow-up reported in the reviewed studies. CONCLUSIONS: OnabotulinumtoxinA therapy is effective, safe and well tolerated in adults with neurogenic bladder dysfunction. Further high-quality prospective trial data are required to determine the optimal dose, injection technique, long-term safety, favourable timing, indications for re-injections, and the impact of concomitant antimuscarinics on onabotulinumtoxinA therapy.
BACKGROUND: Botulinum toxin A (BoNTA) is increasingly used for therapy of neurogenic detrusor overactivity (NDO) refractory to antimuscarinics or where patients are experiencing antimuscarinic-related side effects. OBJECTIVE: The objective was to compare and critically discuss the reported efficacy and safety of BoNTA in adults with neurogenic bladder dysfunction. DATA SOURCES: Studies published between January 1985 and July 2012 were identified in the MEDLINE (PubMed) and SCOPUS databases. STUDY SELECTION, STUDY APPRAISAL AND SYNTHESIS METHODS: A search for studies with onabotulinumtoxinA--the only formulation of BoNTA approved by the US FDA in adults with NDO--was performed. Exclusion criteria were urethral sphincter injection, no separate analysis between onabotulinumtoxinA and other formulations of BoNTA, mean follow-up ≤ 4 weeks and studies with ten or fewer patients. Clinical and urodynamic parameters for efficacy, adverse events (AEs) and tolerability were reviewed to offer recommendations for practice and future research. RESULTS: A total of 28 included studies revealed superior effects of onabotulinumtoxinA compared with placebo in achieving continence, reducing incontinence episodes, improving urodynamic parameters and health-related quality of life. The most frequently reported AEs were de novo intermittent catheterization, urinary retention and asymptomatic urinary infection. LIMITATIONS: Limitations of this review are the inclusion of studies with the level-3 evidence (22/28 studies), the heterogenicity of outcome parameters and time points chosen for follow-up reported in the reviewed studies. CONCLUSIONS: OnabotulinumtoxinA therapy is effective, safe and well tolerated in adults with neurogenic bladder dysfunction. Further high-quality prospective trial data are required to determine the optimal dose, injection technique, long-term safety, favourable timing, indications for re-injections, and the impact of concomitant antimuscarinics on onabotulinumtoxinA therapy.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein Journal: Urology Date: 2003-01 Impact factor: 2.649
Authors: Cristiano M Gomes; Jose E de Castro Filho; Ronald F Rejowski; Flavio E Trigo-Rocha; Homero Bruschini; Tarcisio E P de Barros Filho; Miguel Srougi Journal: Int Braz J Urol Date: 2010 Jan-Feb Impact factor: 1.541
Authors: A Conte; A Giannantoni; S Proietti; S Giovannozzi; G Fabbrini; A Rossi; M Porena; A Berardelli Journal: Eur J Neurol Date: 2011-12-28 Impact factor: 6.089
Authors: Yeun Goo Chung; Khalid Algarrahi; Debra Franck; Duong D Tu; Rosalyn M Adam; David L Kaplan; Carlos R Estrada; Joshua R Mauney Journal: Biomaterials Date: 2014-06-07 Impact factor: 12.479